Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Mkilloran who wrote (18301)	1/28/1999 11:16:00 PM
From: VLAD	Read Replies (1) \| Respond to of 23519

martin, Forgeting about the ED aspects of Vivus I think that any large pharma realizes that those patents to deliver medications to treat premature ejaculation, incontinence and diseases of the prostate are easily worth 100's of millions of dollars if (and I myself do not know) there are generic drugs out there that would help these problems. I think that these "other" problems have a lot of $ making potential if a large pharma with deep pockets can push the R&D to the hilt. Little Vivus doesn't have the cash right now to spend on R&D to rapidly develop such products but in the hands of some serious money, I think they could be sitting on a gold mine.